Lexaria Bioscience’s busy study year is about to get even busier.
The Kelowna company will test to see how its DehydraTech drug delivery technology works in four drug markets, including anti-inflammatories, nicotine replacement therapies, tetrahydrocannabinols and erectile dysfunction. Each study’s goal is to evaluate the rate of absorption and speed with which DehydraTech delivers the drugs being studied into the bloodstream or after oral dosing.
“Our 2021 study program—already the largest in our company’s history—is growing,” Lexaria CEO Chris Bunka said in a press release. “All of our studies are designed to generate must-have data allowing us to have more meaningful business discussions with various industry leaders and, as such, can shorten the time required for positive commercial developments.”
The studies will determine, for example, if anti-inflammatories can be taken at lower doses due to higher bioavailability and brain uptake, and if erectile dysfunction drugs can start working faster than the usual one to two hours currently required to achieve maximum effectiveness.
All Biz Releases Stories